Mebendazole for Systemic Lupus Erythematosus? New 2026 Study Sparks Interest in Repurposed Autoimmune Treatments
A newly published 2026 study has reignited interest in an unlikely candidate for autoimmune disease treatment: Mebendazole.
Best known as an inexpensive anti-parasitic drug used for worm infections, mebendazole is now attracting attention for its potential immune-modulating and anti-inflammatory properties. The excitement follows a new preclinical paper published in Scientific Reports that investigated mebendazole in a mouse model of systemic lupus erythematosus (SLE).
The study was amplified on X by William Makis (@MakisMedicine), whose thread summarized the findings and generated significant engagement among patients interested in repurposed drugs and autoimmune disease research.
But how promising are these findings really? And what does the science actually say?
What Is Lupus (SLE)?
Systemic Lupus Erythematosus (SLE), commonly called lupus, is a chronic autoimmune disease in which the immune system mistakenly attacks the body’s own tissues.
Lupus can affect:
Kidneys
Skin
Joints
Brain
Blood vessels
Heart and lungs
One of the most serious complications is lupus nephritis, where immune complexes damage the kidneys and may eventually lead to kidney failure.
Current lupus treatments include:
Corticosteroids
Immunosuppressants
Methotrexate
Mycophenolate
Biologics like rituximab and belimumab
Hydroxychloroquine
Despite available therapies, many patients continue to experience:
disease flares,
medication side effects,
incomplete responses,
or progressive organ damage.
That is why researchers remain interested in drug repurposing strategies.
The 2026 Mebendazole Lupus Study
The study:
“Efficacy of mebendazole in the spontaneous NZBxNZWF1 animal model of systemic lupus erythematosus”was published in February 2026 in Scientific Reports (Nature).
The researchers used the well-established NZB×NZW F1 mouse model of lupus, which spontaneously develops:
autoantibodies,
immune complex deposition,
kidney inflammation,
and lupus-like disease progression.
This model is widely used in lupus research because it resembles several important features of human SLE.
Key Findings From the Study
1. Reduced Proteinuria (Kidney Damage Marker)
One of the most important findings was a reduction in proteinuria.
Proteinuria refers to excess protein leaking into urine due to kidney damage and is a major marker of lupus nephritis severity.
Mice treated with mebendazole — particularly at 25 mg/kg — showed:
lower urinary protein levels,
improved kidney outcomes,
and reduced signs of renal immune injury.
This is clinically relevant because kidney involvement is one of the most dangerous aspects of lupus.
2. Lower Anti-dsDNA Autoantibodies
The study also found reductions in:
anti-double stranded DNA (anti-dsDNA) antibodies.
These autoantibodies are strongly associated with lupus activity and kidney disease.
Interestingly, mebendazole reduced anti-dsDNA levels in the therapeutic arm of the study, whereas the anti-CD20 comparator did not in this specific experimental setup.
However, this should not be interpreted as proof that mebendazole is superior to established biologics in human lupus.
3. Reduced Immune Complex Deposition in Kidneys
Researchers observed:
decreased glomerular IgG immune complex deposits.
Immune complexes are a hallmark of lupus pathology and contribute heavily to kidney inflammation and tissue destruction.
Reducing these deposits suggests potential disease-modifying activity rather than merely symptom suppression.
4. Possible Immune-Modulating Effects
One especially intriguing finding involved immune cell behavior.
The authors suggested that mebendazole may:
restore defective ERK signaling,
inhibit inflammatory p38 signaling,
and improve regulatory immune function.
These pathways are highly relevant in lupus biology.
The proposed mechanisms involve abnormal immune activation in:
T cells,
B cells,
cytokine signaling networks.
Although still preliminary, this raises the possibility that mebendazole may possess broader immune-regulatory properties beyond its anti-parasitic effects.
Why Mebendazole Is Getting Attention Beyond Parasites
Mebendazole has increasingly attracted scientific interest because researchers have observed potential:
anti-cancer,
anti-inflammatory,
metabolic,
and immune-modulating effects.
Studies have explored mebendazole in:
glioblastoma,
colon cancer,
melanoma,
parasitic infections,
inflammatory conditions,
and now lupus.
Unlike many newer drugs, mebendazole is:
inexpensive,
widely available,
orally administered,
and has decades of safety data for anti-parasitic use.
That makes it an attractive repurposing candidate if efficacy can eventually be confirmed.
Mebendazole vs Fenbendazole: Important Differences
Online discussions often group mebendazole and fenbendazole together because both belong to the benzimidazole family.
However, they are not identical drugs.
Fenbendazole is primarily a veterinary medication, whereas mebendazole is approved for human use in many countries.
Researchers have proposed that mebendazole may influence ERK signaling differently from fenbendazole, potentially giving it distinct immunological effects.
This distinction matters because internet communities sometimes incorrectly assume all benzimidazoles behave similarly.
At present:
lupus evidence exists for mebendazole in mice,
but not for fenbendazole.
Important Limitations of the Study
While the results are interesting, several important caveats remain.
Preclinical Only
This was a mouse study — not a human clinical trial.
Many therapies that perform well in lupus mouse models ultimately fail in humans.
Human lupus is extraordinarily complex and heterogeneous.
Small Sample Sizes
The study used relatively small groups:
approximately 8–10 mice per treatment arm.
That is common in preclinical research but limits statistical certainty.
No Human Dosing Guidance
Mouse doses do not directly translate into safe or effective human dosing.
Additionally, mebendazole has:
variable oral absorption,
limited bioavailability,
and complex pharmacokinetics in humans.
Whether therapeutic immune-modulating levels can be reliably achieved in lupus patients remains unknown.
Mechanism Still Exploratory
The proposed ERK/p38 signaling mechanisms are biologically plausible but not definitively proven.
Further mechanistic studies are needed.
Why This Study Still Matters
Despite the limitations, the study is scientifically important for several reasons.
1. Lupus Needs Better Therapies
SLE remains difficult to treat and can cause severe organ damage despite modern therapies.
New treatment strategies are urgently needed.
2. Repurposed Drugs Can Succeed
Some major therapies originated from repurposed medications.
For example:
Hydroxychloroquine itself began as an anti-malarial drug before becoming foundational in lupus treatment.
Repurposing can dramatically reduce:
development costs,
safety uncertainty,
and time to clinical use.
3. The Kidney Findings Are Particularly Interesting
Lupus nephritis is one of the strongest predictors of:
hospitalization,
chronic kidney disease,
and mortality in SLE.
Any therapy showing meaningful kidney protection deserves further investigation.
Could Mebendazole Eventually Be Tested in Humans?
Possibly.
The authors concluded that their findings:
“support further investigation of MBZ as a repositioned candidate for SLE.”
That does not mean mebendazole works for lupus in humans today.
But it may justify:
additional animal studies,
mechanistic research,
and eventually early-phase human trials.
Whether it ultimately succeeds clinically remains unknown.
Social Media Reaction and Patient Interest
The X thread by William Makis generated strong engagement from:
lupus patients,
autoimmune communities,
and followers of repurposed-drug research.
Many users asked about:
dosing,
scleroderma overlap,
safety,
and combination protocols.
This reflects growing public interest in lower-cost repurposed medicines, particularly for chronic diseases with limited treatment options.
However, patients should avoid self-experimentation without medical supervision.
Final Verdict
The 2026 lupus mebendazole study is a legitimate and scientifically interesting preclinical paper — not internet hype.
The data suggest that Mebendazole may reduce:
proteinuria,
autoimmune antibody production,
and kidney immune damage
in a well-established lupus mouse model.
Still, there is currently:
no human lupus evidence,
no validated dosing strategy,
and no proof of clinical benefit in patients.
The findings are promising enough to justify further investigation, but far too early to consider mebendazole an established lupus therapy.
For now, the study is best viewed as:
an intriguing proof-of-concept,
a potential repurposed-drug candidate,
and another example of how old medicines may still hold untapped therapeutic potential.
.png)
.png)
Comments
Post a Comment